# EDGAR Filing Document

**Accession Number:** 0001477449
**File Stem:** 0001477449-25-000122
**Filing Date:** 2025-12
**Character Count:** 7698
**Document Hash:** 094479d034503200b2e2fbe3e55903b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477449-25-000122.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001477449-25-000122

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251209

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Teladoc Health, Inc.
- **CENTRAL INDEX KEY:** 0001477449
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043705970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37477
- **FILM NUMBER:** 251568055

**BUSINESS ADDRESS:**
- **STREET 1:** 155 E 44TH STREET
- **STREET 2:** SUITE 1700
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 2036352002

**MAIL ADDRESS:**
- **STREET 1:** 155 E 44TH STREET
- **STREET 2:** SUITE 1700
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Teladoc, Inc.
- **DATE OF NAME CHANGE:** 20091123

?xml version='1.0' encoding='ASCII'? tdoc-20251209

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**___________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported) December 9, 2025**

**___________________________________**

**Teladoc Health, Inc.**

**(Exact name of registrant as specified in its charter)**

**___________________________________**

---

| | | |
|:---|:---|:---|
| **Delaware**<br>**(State or other jurisdiction of** <br>**incorporation or organization)** | **001-37477**<br>**(Commission File Number)** | **04-3705970**<br>**(I.R.S. Employer Identification Number)** |
| **155 E 44th Street Suite 1700** <br>**New York, NY 10017** | **155 E 44th Street Suite 1700** <br>**New York, NY 10017** | **155 E 44th Street Suite 1700** <br>**New York, NY 10017** |
| **(Address of principal executive offices and zip code)** | **(Address of principal executive offices and zip code)** | **(Address of principal executive offices and zip code)** |
| **(203) 635-2002** | **(203) 635-2002** | **(203) 635-2002** |
| **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** |

---

**___________________________________**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

**☐** **Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**☐** **Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**☐** **Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

**☐** **Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

---

| | | |
|:---|:---|:---|
| **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** |
| **<u>Title of each class</u>** | **<u>Trading Symbol</u>** | **<u>Name of each exchange on which registered</u>** |
| **Common stock, par value $0.001 per share** | **TDOC** | **The New York Stock Exchange** |

---

**Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.**

**Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☐**

**If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.**

------

**Item 5.02.&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 9, 2025, Teladoc Health, Inc. (the "Company" or "we") amended its 2023 Employment Inducement Incentive Award Plan (as amended, the "2023 Inducement Plan") solely to increase the number of shares of common stock, par value $0.001 per share ("Common Stock"), reserved for issuance under the 2023 Inducement Plan by 1,780,000 shares, to a new total of 7,280,000 shares of Common Stock. The amendment to the Inducement Plan is filed as Exhibit 10.1 hereto and incorporated herein by reference. As previously disclosed, the 2023 Inducement Plan was adopted by the Board without stockholder approval pursuant to NYSE Rule 303A.08.

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Description</u> |
| <u>[10.1](exhibit1015.htm)</u> | <u>[Third Amendment to Teladoc Health, Inc. 2023 Employment Inducement Award Plan.](exhibit1015.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 12, 2025

---

| | |
|:---|:---|
| **Teladoc Health, Inc.** | **Teladoc Health, Inc.** |
| By: | /s/ Adam C. Vandervoort |
| Name: | Adam C. Vandervoort |
| Title: | Chief Legal Officer and Secretary |

---

## Exhibit 10.1

**Exhibit 10.1**

**THIRD AMENDMENT TO**

**TELADOC HEALTH, INC.**

**2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN**

The 2023 Employment Inducement Incentive Award Plan (the "<u>Plan</u>") of Teladoc Health, Inc., a Delaware corporation (the "<u>Company</u>"), is hereby amended, effective as of December 9, 2025 (the "<u>Effective Date</u>"), as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.**Amendment to Section 11.27 of the Plan**. Section 11.27 of the Plan is hereby deleted and replaced in its entirety with the following:

"***Overall Share Limit***" means 7,280,000 Shares."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.**Effect on the Plan**. This Amendment shall not constitute a waiver, amendment or modification of any provision of the Plan not expressly referred to herein. Except as expressly amended or modified herein, the provisions of the Plan are and shall remain in full force and effect and are hereby ratified and confirmed. On and after the Effective Date, each reference in the Plan to "this Plan," "herein," "hereof," "hereunder" or words of similar import shall mean and be a reference to the Plan as amended hereby. To the extent that a provision of this Amendment conflicts with or differs from a provision of the Plan, such provision of this Amendment shall prevail and govern for all purposes and in all respects.

<br>